Company Profile

  • 1997

    Bio-Tissue® Founded

  • 2001

    TissueTech™ founded & received FDA designation for wound healing for AmnioGraft®

     

  • 2003

    Company received FDA 510K Clearance for PROKERA®: First amniotic allograft for use without sutures

  • 2010

    Company launches AmnioGuard®: first umbilical cord allograft for clinical use

  • 2011

    Amniox® Medical founded

  • 2013

    Series A Funding – $10M

  • 2015

    Series B funding – $15M

  • 2016

    250,000 applications of the Company’s products

Company History

TissueTech, Inc. is the leader in innovative technologies using products derived from human amniotic and umbilical cord tissues.  Since its inception in 1997, the Company has pioneered the clinical application of human placental tissues – more than 300,000 patients have been treated with TissueTech products and the Company’s groundbreaking scientific and clinical achievements have been documented in more than 300 peer-reviewed publications.

TissueTech was founded in 2001 as the parent entity for Bio-Tissue Inc., which develops and markets regenerative therapies for treating the ocular surface. In 1997, Bio-Tissue was the first company to introduce the use of cryopreserved amniotic membrane tissue for clinical application, by utilizing its proprietary CryoTek technology, proven to preserve the innate biological and structural properties of the amniotic membrane tissue.

Initial research on the company’s proprietary technology began in 1986,  and was led by the company’s  –co-founder Scheffer C. G. Tseng, M.D., Ph.D., with a grant from the National Institutes of Health (NIH). Dr. Tseng spearheaded efforts in the scientific and clinical community to utilize the innate regenerative properties of human umbilical cord and amniotic membrane tissue to promote wound healing. Since then, the company has received 30 years of continuous National Institutes of Health (NIH) support to support ongoing scientific research. This groundbreaking  research has led to the development of products at the forefront of innovation that are used by doctors around the world.

Today, Bio-Tissue leads the ophthalmic market providing the only tissue recognized by the U.S. Food and Drug Administration (FDA) to reduce inflammation and prevent scarring and angiogenesis of the ocular surface. In 2011, a second commercial entity, Amniox Medical, Inc. was founded to market the company’s proprietary technology in the orthopedic, wound care, and spine markets. In its short history, Amniox Medical has become a leader in these sectors.

TissueTech continues to receive recognition for its many accomplishments. In 2014, the company was recognized as one of the  5000 Fastest Growing Incorporated Private Companies in the United States.The Greater Miami Chamber of Commerce named its business unit Bio-Tissue Minority-Owned Business of the Year. In 2015, TissueTech was the recipient of the prestigious Tibbetts Award from the U.S. Small Business Administration (SBA) in recognition of its significant contributions to the field of regenerative medicine.  In 2017, the Company received the award for Spine Technology Innovation in Biologics at the North American Spine Society annual meeting.